DTaP-polio combo vaccine does well in Phase III trials
Positive Phase III results from a vaccine that combines four existing immunizations together were reported online by Pediatric Infectious Disease Journal.
Positive Phase III results from a vaccine that combines four existing immunizations together were reported online by Pediatric Infectious Disease Journal.
Kinrix is GlaxoSmithKline's name for a combination of inactivated polio and a DTaP (diphtheria, tetanus, and acellular pertussis) vaccinations. The combined product would require one shot, not two.
The phase III results showed immune response and safety profile to the individually-administered shots. It enrolled over 4,000 children ages 4 to 6. The most common adverse event was injection site pain (over 50%, followed by redness, swelling, and increase in arm circumference (all over 25%).
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
